NYSEMKT: XTNTXtant Medical Holdings Inc Stock
$0.65+0.02 (+3.17%)
Updated Oct 7, 2024
XTNT Price
$0.65
Fair Value Price
N/A
Market Cap
$84.70M
52 Week Low
$0.51
52 Week High
$1.45
P/E
-32.5x
P/B
1.88x
P/S
0.74x
PEG
N/A
Dividend Yield
N/A
Revenue
$110.94M
Earnings
-$3.33M
Gross Margin
61.6%
Operating Margin
-1.39%
Profit Margin
-3%
Debt to Equity
1.12
Operating Cash Flow
-$16M
Beta
0.21
Next Earnings
Nov 7, 2024
Ex-Dividend
N/A
Next Dividend
N/A
XTNT Overview
Xtant Medical Holdings, Inc. designs, and develops orthobiologics and spinal implant fixation systems to facilitate spinal fusion in complex spine, deformity, and degenerative procedures. The company is headquartered in Belgrade Montana, Montana and currently employs 166 full-time employees. The firm operates through the development, manufacture and marketing of regenerative medical products and devices segment. Its biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, BacFast HD, OsteoSTX, hMatrix and 3Demin products, as well as other allografts. Its products serve the needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, foot and ankle surgeries. The company also processes and distributes sports allografts, milled spinal allografts and allografts for multi-disciplinary applications.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how XTNT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
XTNT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
XTNT is good value based on its book value relative to its share price (1.88x), compared to the US Medical Devices industry average (3.98x)
P/B vs Industry Valuation
XTNT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more XTNT due diligence checks available for Premium users.
Be the first to know about important XTNT news, forecast changes, insider trades & much more!
XTNT News
Valuation
XTNT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-32.5x
Industry
40.54x
Market
26.63x
XTNT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.88x
Industry
3.98x
XTNT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
XTNT's financial health
Profit margin
Revenue
$29.9M
Net Income
-$3.9M
Profit Margin
-12.9%
XTNT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
XTNT's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$95.6M
Liabilities
$50.6M
Debt to equity
1.12
XTNT's short-term assets ($68.97M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XTNT's short-term assets ($68.97M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XTNT's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
XTNT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.1M
Investing
-$480.0k
Financing
$6.4M
XTNT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
XTNT vs Medical Device Stocks
Xtant Medical Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.